IL17A and multiple sclerosis: A further consideration is the success in therapeutic targeting of inflammatory Th17 cells in conditions such a psoriasis, or multiple sclerosis via antibodies against interleukin-17A (IL-17A) or IL-12p40 (Patel and Kuchroo, 2015).